Balanced news tone
News Sentiment
MNOV sentiment intelligence
MediciNova Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
51
Balanced news tone
38 relevant articles
News tone and price action are not far from neutral.
87/100 classification confidence.
directly relevant articles
high-authority source matches
-2.8% over one week, +13.0% over four weeks, trend inactive, and near fair-value range.
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
87/100 classification
One-week reaction
-2.8%
Price reacting lower
Trend fit
Trend inactive
13.0% over four weeks
Fair value
-12.1%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
5
Neutral
31
Negative
2
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
GlobeNewswire
Direct company coverage
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 12:00
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
ALS patients ineligible for trials join MediciNova's 200-person study
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 12:00
- Source
- Stock Titan
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Ad Hoc News
Direct company coverage
MediciNova Inc outlines its biotech pipeline as investors watch MN-166 progress
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 12:39
- Source
- Ad Hoc News
dars.gov.et
Direct company coverage
Medicinova Inc (MNOV) Holds Steady Near Support After Modest Advance - Factor Crowding
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 14:31
- Source
- dars.gov.et
dars.gov.et
Direct company coverage
Medicinova Inc (MNOV) Surges 7.6% as Biotech Stock Tests Resistance at $1.49 - Buffered ETF
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 02 Jul 2026 02:33
- Source
- dars.gov.et
GlobeNewswire
Direct company coverage
MediciNova CEO Provides Shareholder Update
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 12:00
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
MediciNova awaits Q3 data as ALS study hits 100 patients
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 07:00
- Source
- Stock Titan
Investing.com Canada
Direct company coverage
Form 4 MediciNova Inc For: 25 June By Investing.com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 07:00
- Source
- Investing.com Canada
Stock Titan
Direct company coverage
MediciNova (MNOV) director awarded 44,500 stock options
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
MediciNova (MNOV) director receives grant of 44,500 stock options
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
MediciNova (MNOV) director Nicole Lemerond receives 44,500 stock options grant
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 07:00
- Source
- Stock Titan
dars.gov.et
Direct company coverage
Medicinova Inc (MNOV) Holds Near Support Amid Modest Decline - Range Breakout
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 24 Jun 2026 07:00
- Source
- dars.gov.et
MT Newswires
Direct company coverage
MediciNova Granted US Patent Notice of Allowance for Ibudilast Combination to Treat Brain Cancer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 12:34
- Source
- MT Newswires
GlobeNewswire
Direct company coverage
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 12:00
- Source
- GlobeNewswire
Ad Hoc News
Direct company coverage
MediciNova Inc stock (US58468P2038): Nasdaq biotech share edges higher while valuation metrics stay subdued
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 Jun 2026 07:00
- Source
- Ad Hoc News
DonanımHaber
Direct company coverage
Medicinova Inc (MNOV) Edges Higher on Modest Volume, Faces Key Resistance at $1.41 - Shakeout Pattern
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 28 May 2026 07:00
- Source
- DonanımHaber
DonanımHaber
Direct company coverage
Medicinova (MNOV) Slides 4% as Stock Tests Key Support Near $1.24 - Hagopian Line
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 07:00
- Source
- DonanımHaber
dars.gov.et
Direct company coverage
Medicinova Inc (MNOV) Slips to $1.33 as Shares Retreat 2.92% - Stop Hunt
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 07:00
- Source
- dars.gov.et
dars.gov.et
Direct company coverage
Medicinova (MNOV) Slides 4% as Stock Tests Key Support Near $1.24 - MA Crossover
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 07:00
- Source
- dars.gov.et
dars.gov.et
Direct company coverage
Medicinova (MNOV) Slides 4% as Stock Tests Key Support Near $1.24 - Double EMA
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 07:00
- Source
- dars.gov.et
GlobeNewswire
Direct company coverage
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 23:00
- Source
- GlobeNewswire
GlobeNewswire
Direct company coverage
MediciNova Announces Completion of Last Patient Last Visit
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 07:00
- Source
- GlobeNewswire
Market source
Direct company coverage
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 16 May 2026 07:00
- Source
- Market source
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Associated Press
Direct company coverage
MediciNova: Q1 Earnings Snapshot
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 22:44
- Source
- Associated Press
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
GlobeNewswire
Direct company coverage
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 27 Apr 2026 23:00
- Source
- GlobeNewswire